ESMO 2023: A new immunotherapy, volrustomig, for the first-line treatment of advanced kidney cancer
Blocking the action of two proteins in cancer cells (PD-1 [...]
Blocking the action of two proteins in cancer cells (PD-1 [...]
A recent study published in Journal of Clinical Medicine last [...]